Casa
asdas

ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response

Por um escritor misterioso

Descrição
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension - Deodhar
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. - Abstract - Europe PMC
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice - The Lancet Rheumatology
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Management of axial spondyloarthritis
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Table 6, Details of Included Studies - Upadacitinib (Rinvoq) - NCBI Bookshelf
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Oral Abstracts - 2020 - International Journal of Rheumatic Diseases - Wiley Online Library
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
A and B, Percentages of patients in the golimumab (GLM) and placebo
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. - Abstract - Europe PMC
de por adulto (o preço varia de acordo com o tamanho do grupo)